Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Assets (2020 - 2025)

Rani Therapeutics Holdings has reported Assets over the past 6 years, most recently at $58.6 million for Q4 2025.

  • Quarterly results put Assets at $58.6 million for Q4 2025, up 60.02% from a year ago — trailing twelve months through Dec 2025 was $58.6 million (up 60.02% YoY), and the annual figure for FY2025 was $58.6 million, up 60.02%.
  • Assets for Q4 2025 was $58.6 million at Rani Therapeutics Holdings, up from $10.1 million in the prior quarter.
  • Over the last five years, Assets for RANI hit a ceiling of $137.0 million in Q3 2021 and a floor of $10.1 million in Q3 2025.
  • Median Assets over the past 5 years was $70.4 million (2023), compared with a mean of $72.1 million.
  • Peak annual rise in Assets hit 60.02% in 2025, while the deepest fall reached 76.71% in 2025.
  • Rani Therapeutics Holdings' Assets stood at $124.2 million in 2021, then fell by 13.03% to $108.0 million in 2022, then crashed by 46.39% to $57.9 million in 2023, then tumbled by 36.75% to $36.6 million in 2024, then skyrocketed by 60.02% to $58.6 million in 2025.
  • The last three reported values for Assets were $58.6 million (Q4 2025), $10.1 million (Q3 2025), and $16.9 million (Q2 2025) per Business Quant data.